CONMED (NYSE:CNMD) Announces FY 2026 Earnings Guidance

Key Points

• CONMED issued FY 2026 guidance for adjusted EPS of $4.54–$4.61 and revenue of approximately $1.4 billion, broadly matching analyst consensus.
• The company’s latest quarterly results showed EPS of $1.04, beating estimates by $0.04, while revenue of $335.56 million narrowly missed forecasts and declined 0.7% year over year.
• Shares opened down 1.1% at $45.20, while analyst sentiment remained cautious: seven analysts rated the stock Hold and one Sell, with a consensus target price of $44.

CONMED (NYSE:CNMD - Get Free Report) updated its FY 2026 earnings guidance on Friday. The company provided EPS guidance of 4.540-4.610 for the period, compared to the consensus EPS estimate of 4.540. The company issued revenue guidance of $1.4 billion, compared to the consensus revenue estimate of $1.4 billion.

CONMED Stock Down 1.1%

Shares of CNMD opened at $45.20 on Friday. The company has a current ratio of 1.48, a quick ratio of 0.69 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $1.35 billion, a PE ratio of 18.68, a P/E/G ratio of 2.09 and a beta of 0.94. The firm's 50 day moving average is $47.20 and its 200-day moving average is $41.45. CONMED has a 12 month low of $31.44 and a 12 month high of $53.66.

CONMED (NYSE:CNMD - Get Free Report) last released its earnings results on Wednesday, October 28th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.00 by $0.04. The company had revenue of $335.56 million for the quarter, compared to analyst estimates of $336.28 million. CONMED had a return on equity of 14.03% and a net margin of 5.36%. CONMED's quarterly revenue was down .7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.08 EPS. Equities research analysts forecast that CONMED will post 4.54 EPS for the current year.

Analyst Ratings Changes

CNMD has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on CONMED from $45.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday. BMO Capital Markets assumed coverage on shares of CONMED in a report on Wednesday, July 8th. They issued a "market perform" rating and a $36.00 price objective for the company. Weiss Ratings raised shares of CONMED from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, October 21st. Piper Sandler reissued a "neutral" rating and issued a $45.00 price objective (up from $39.00) on shares of CONMED in a research note on Thursday, July 30th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of CONMED in a research report on Monday, July 13th. Seven analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, CONMED has an average rating of "Reduce" and a consensus target price of $44.00.

CONMED Company Profile

CONMED Corporation is a medical technology company that develops, manufactures, and sells surgical devices and related equipment. Its products are used by hospitals, ambulatory surgery centers, and other healthcare providers in orthopedic and general surgery procedures.

The company's orthopedic portfolio includes arthroscopy systems, powered surgical instruments, sports medicine products, tissue ablation systems, implants, and related accessories. Its general surgery offerings include electrosurgical equipment, insufflation systems, smoke evacuation products, surgical visualization technologies, and devices used in minimally invasive procedures.

Founded in 1970, CONMED serves healthcare customers through direct sales and distribution channels in the United States and international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.